CN102329775A - 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 - Google Patents
一种对吉西他滨耐药的人胰腺癌细胞系及其应用 Download PDFInfo
- Publication number
- CN102329775A CN102329775A CN2010102257411A CN201010225741A CN102329775A CN 102329775 A CN102329775 A CN 102329775A CN 2010102257411 A CN2010102257411 A CN 2010102257411A CN 201010225741 A CN201010225741 A CN 201010225741A CN 102329775 A CN102329775 A CN 102329775A
- Authority
- CN
- China
- Prior art keywords
- pancreatic cancer
- cell
- human pancreatic
- cancer cell
- pancreas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 45
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 45
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 45
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 36
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 23
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 6
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 47
- 238000011580 nude mouse model Methods 0.000 claims description 24
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 17
- 238000011081 inoculation Methods 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- 238000010171 animal model Methods 0.000 claims description 13
- 235000015097 nutrients Nutrition 0.000 claims description 13
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 229940056360 penicillin g Drugs 0.000 claims description 10
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000004026 insulin derivative Substances 0.000 claims description 6
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 5
- 229960003942 amphotericin b Drugs 0.000 claims description 5
- 238000013016 damping Methods 0.000 claims description 5
- 229940000406 drug candidate Drugs 0.000 claims description 5
- 229930183010 Amphotericin Natural products 0.000 claims description 4
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 4
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 229940009444 amphotericin Drugs 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 102000002070 Transferrins Human genes 0.000 claims description 3
- 108010015865 Transferrins Proteins 0.000 claims description 3
- 238000009395 breeding Methods 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000009456 molecular mechanism Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 79
- 210000001519 tissue Anatomy 0.000 description 13
- 230000012010 growth Effects 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 238000010827 pathological analysis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000002548 cytokinetic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010225741.1A CN102329775B (zh) | 2010-07-13 | 2010-07-13 | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010225741.1A CN102329775B (zh) | 2010-07-13 | 2010-07-13 | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102329775A true CN102329775A (zh) | 2012-01-25 |
CN102329775B CN102329775B (zh) | 2015-08-19 |
Family
ID=45481740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010225741.1A Expired - Fee Related CN102329775B (zh) | 2010-07-13 | 2010-07-13 | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102329775B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103898043A (zh) * | 2014-03-11 | 2014-07-02 | 山东大学附属千佛山医院 | 细胞饲养层及其在培养人原代肿瘤细胞中的应用 |
CN104946594A (zh) * | 2014-11-12 | 2015-09-30 | 福建医科大学 | 人胰腺癌耐吉西他滨细胞系的建立方法及该细胞系的应用 |
CN108315303A (zh) * | 2018-01-30 | 2018-07-24 | 复旦大学附属中山医院 | 一种制备人胆囊癌吉西他滨耐药细胞系的方法 |
CN108866001A (zh) * | 2018-08-02 | 2018-11-23 | 郭世伟 | 人胰腺癌神经浸润细胞系 |
CN112662628A (zh) * | 2021-01-13 | 2021-04-16 | 王伟 | 一种对吉西他滨耐药的胆囊癌细胞株及其应用 |
CN115029316A (zh) * | 2022-06-20 | 2022-09-09 | 华中科技大学同济医学院附属协和医院 | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101008003A (zh) * | 2006-11-29 | 2007-08-01 | 复旦大学附属肿瘤医院 | 一种胰腺癌高肝转移细胞系 |
-
2010
- 2010-07-13 CN CN201010225741.1A patent/CN102329775B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101008003A (zh) * | 2006-11-29 | 2007-08-01 | 复旦大学附属肿瘤医院 | 一种胰腺癌高肝转移细胞系 |
Non-Patent Citations (4)
Title |
---|
朱志霞等: "吉西他滨与埃罗替尼联用对人胰腺癌细胞生长的影响", 《解放军医学杂志》 * |
李小颖等: "SW1990和Capan-2红色荧光标记胰腺癌移植肿瘤模型的建立和比较", 《中国比较医学杂志》 * |
要洁等: "人胰腺癌吉西他滨耐药细胞系的建立及耐药特性的检测", 《实用肿瘤杂志》 * |
郭俊超等: "胰腺癌耐药细胞株SW1990/FU的建立、鉴定及生物学特性", 《中国医学科学院学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103898043A (zh) * | 2014-03-11 | 2014-07-02 | 山东大学附属千佛山医院 | 细胞饲养层及其在培养人原代肿瘤细胞中的应用 |
CN104946594A (zh) * | 2014-11-12 | 2015-09-30 | 福建医科大学 | 人胰腺癌耐吉西他滨细胞系的建立方法及该细胞系的应用 |
CN108315303A (zh) * | 2018-01-30 | 2018-07-24 | 复旦大学附属中山医院 | 一种制备人胆囊癌吉西他滨耐药细胞系的方法 |
CN108866001A (zh) * | 2018-08-02 | 2018-11-23 | 郭世伟 | 人胰腺癌神经浸润细胞系 |
CN108866001B (zh) * | 2018-08-02 | 2023-05-02 | 郭世伟 | 人胰腺癌神经浸润细胞系 |
CN112662628A (zh) * | 2021-01-13 | 2021-04-16 | 王伟 | 一种对吉西他滨耐药的胆囊癌细胞株及其应用 |
CN112662628B (zh) * | 2021-01-13 | 2023-11-03 | 王伟 | 一种对吉西他滨耐药的胆囊癌细胞株及其应用 |
CN115029316A (zh) * | 2022-06-20 | 2022-09-09 | 华中科技大学同济医学院附属协和医院 | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
CN115029316B (zh) * | 2022-06-20 | 2024-04-30 | 华中科技大学同济医学院附属协和医院 | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102329775B (zh) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102250840B (zh) | 一种人胰腺癌细胞系及其应用 | |
CN103627673B (zh) | 一种人脑胶质瘤细胞系及其建立方法和应用 | |
CN110475860A (zh) | 使用肿瘤组织的原代癌细胞的三维培养 | |
CN102329775B (zh) | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 | |
CN102465113A (zh) | 一种人肝癌细胞系及其应用 | |
CN106574242A (zh) | 源自单细胞的类器官 | |
CN102719403B (zh) | 一种人胰腺腺鳞癌细胞系及其建立方法和应用 | |
CN101982178A (zh) | 人结肠癌移植瘤小鼠模型的建立方法 | |
CN104694476A (zh) | 一种人非小细胞肺癌细胞系及其建立方法和应用 | |
CN111793604B (zh) | 一种耐奥希替尼的人非小细胞肺癌细胞株h1975/or及其应用 | |
CN109392843A (zh) | 基于类器官方法构建卵巢癌移植瘤模型及应用 | |
CN109182271A (zh) | 基于类器官方法构建正常免疫小鼠人胃癌移植瘤模型的方法和应用 | |
CN114075539A (zh) | 构建原位原发膀胱癌动物模型的方法 | |
CN114717190A (zh) | 一种人乳腺恶性叶状肿瘤细胞系bpt0713及其应用 | |
CN104745530A (zh) | 一种人肝细胞癌细胞系及其建立方法和应用 | |
CN113667645B (zh) | 一种犬乳腺癌细胞系、其建立方法及应用 | |
CN105255832A (zh) | 一种人胆管癌细胞系及其应用 | |
CN105861441A (zh) | 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 | |
CN106676074B (zh) | 一种体外扩增肝癌干细胞的方法 | |
CN112210538A (zh) | 一种人食管鳞癌细胞系ncce1、建立方法及其应用 | |
JP2015167521A (ja) | 乳癌の骨髄高転移性マウス乳癌細胞株の樹立方法 | |
CN111635912A (zh) | 一种将肝细胞诱导为肝癌细胞的基因组合及其应用 | |
CN103911343B (zh) | 一种多器官转移人膀胱癌细胞 | |
CN114606192B (zh) | Kras/Lkb1突变型非小细胞肺癌类器官培养液及培养方法 | |
CN108977410B (zh) | 中国人胰腺癌原位癌细胞系 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150928 Address after: 201203, room 3, building 998, 201 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Patentee after: Pioneer medical research (Shanghai) Co.,Ltd. Patentee after: SHANGHAI CHANGHAI Hospital Address before: 201203 Shanghai City Harley Road, Zhangjiang High Tech Park of Pudong New Area No. 965 Room 301 Patentee before: Shanghai ChemPartner Co.,Ltd. Patentee before: Shanghai Changhai Hospital |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 |